# Plasma-Lyte 148® versUs Saline Study

> **NCT02721654** · PHASE4 · COMPLETED · sponsor: **The George Institute** · enrollment: 5037 (actual)

## Conditions studied

- Hypovolemia

## Interventions

- **DRUG:** Plasma-Lyte 148®
- **DRUG:** 0.9% sodium chloride

## Key facts

- **NCT ID:** NCT02721654
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 5037 (ACTUAL)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721654, "Plasma-Lyte 148® versUs Saline Study". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02721654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*